24.80
-1.51 (-5.74%)
| Previous Close | 26.31 |
| Open | 26.10 |
| Volume | 1,488,385 |
| Avg. Volume (3M) | 3,019,562 |
| Market Cap | 3,154,543,360 |
| Price / Sales | 80.36 |
| Price / Book | 9.60 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Operating Margin (TTM) | -583.86% |
| Diluted EPS (TTM) | -11.24 |
| Total Debt/Equity (MRQ) | 18.94% |
| Current Ratio (MRQ) | 3.73 |
| Operating Cash Flow (TTM) | -291.17 M |
| Levered Free Cash Flow (TTM) | -169.99 M |
| Return on Assets (TTM) | -101.07% |
| Return on Equity (TTM) | -247.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alumis Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 53.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 31 Dec 2025 | 15,139,706 |
| Foresite Capital Management V, Llc | 31 Dec 2025 | 5,779,348 |
| Venbio Partners Llc | 31 Dec 2025 | 4,619,803 |
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 4,247,670 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (Raymond James, 85.48%) | Buy |
| Median | 42.00 (69.36%) | |
| Low | 37.00 (Chardan Capital, 49.19%) | Buy |
| Average | 41.75 (68.35%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 25.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 11 Mar 2026 | 46.00 (85.48%) | Buy | 26.34 |
| Stifel | 25 Feb 2026 | 44.00 (77.42%) | Buy | 29.39 |
| Chardan Capital | 21 Jan 2026 | 37.00 (49.19%) | Buy | 26.68 |
| HC Wainwright & Co. | 09 Jan 2026 | 40.00 (61.29%) | Buy | 19.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Alumis to Participate in Upcoming February Investor Conferences |
| 09 Jan 2026 | Announcement | Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |